Fact-checked by Grok 2 weeks ago

L-selectin

L-selectin, also known as CD62L, is a type-I transmembrane and expressed on the surface of most circulating leukocytes, including , , and monocytes, where it mediates the initial tethering and rolling of these cells on vascular during immune responses. Its structure consists of an N-terminal domain responsible for carbohydrate-specific ligand binding, followed by an epidermal growth factor-like domain, two complement regulatory protein repeats, a transmembrane region, and a short 17-amino-acid cytoplasmic that lacks enzymatic activity but facilitates intracellular signaling. L-selectin binds to sialylated and fucosylated glycoproteins such as GlyCAM-1, , and MAdCAM-1 on high endothelial venules, enabling lymphocyte homing to secondary lymphoid organs and neutrophil recruitment to inflammatory sites. Beyond , L-selectin exhibits signaling capabilities upon engagement, triggering tyrosine phosphorylation of intracellular proteins, increases in cytosolic calcium, and activation of pathways like MAP kinase, which prime leukocytes for firm adhesion via and subsequent transmigration. This process is tightly regulated by ectodomain shedding mediated by the metalloprotease ADAM17, which reduces surface expression and generates soluble L-selectin to modulate inflammatory responses and establish leukocyte during . Expressed at high levels (approximately 50,000–70,000 molecules per cell) and preferentially localized to microvilli, L-selectin is downregulated upon leukocyte activation, ensuring directed trafficking. L-selectin plays essential roles in both innate and adaptive immunity, facilitating immune surveillance through lymphocyte recirculation, contributing to pathogen clearance, and influencing conditions like and when dysregulated. As one of three family members (alongside and P-selectin), it operates in a calcium-dependent manner and is critical for the multi-step paradigm of , with its ligands often sulfated to enhance binding affinity under shear flow.

Structure and Biochemistry

Gene and Protein Overview

L-selectin is encoded by the SELL gene, located on the long arm of human at cytogenetic band 1q24.2. This gene spans approximately 21 kb and comprises 9 exons, producing a mature mRNA transcript that translates into a 372-amino-acid protein precursor. The SELL locus is positioned in tandem with the genes for the related (SELE) and P-selectin (SELP), reflecting their shared evolutionary origins within the selectin family. The L-selectin protein, also known as CD62 antigen-like family member L (CD62L), is a type I transmembrane with a predicted core molecular weight of kDa, though post-translational modifications such as N-linked increase its apparent size to 74–100 kDa depending on the leukocyte subtype. It features a short cytoplasmic tail, a single , and an extracellular region oriented toward the cell surface, enabling its role in cell-cell interactions. This structure positions L-selectin as a key mediator of leukocyte dynamics in the vasculature. L-selectin was initially discovered in the early as the MEL-14 antigen on murine lymphocytes, recognized for its involvement in lymph node homing. The murine cDNA encoding this antigen was cloned in 1989 through expression screening using the MEL-14 , revealing its homology to a novel family of calcium-dependent molecules. The human SELL homolog was isolated shortly afterward in 1989, confirming its conservation and functional parallels across species. Within the selectin family, L-selectin shares significant sequence similarity—approximately 60–70% identity in extracellular domains—with E- and P-selectins, underscoring their evolutionary divergence from a common ancestral .

Domains and Post-Translational Modifications

L-selectin is a type I transmembrane characterized by a modular extracellular domain, a single transmembrane , and a short cytoplasmic tail. The extracellular portion consists of an N-terminal calcium-dependent C-type lectin-like domain (CTLD), which mediates carbohydrate-based ligand recognition, an (EGF)-like domain that stabilizes the overall structure through interactions with the CTLD, and two short consensus repeats (SCRs), also known as complement control protein modules, which extend the molecule and position the CTLD for optimal binding. The anchors L-selectin to the plasma membrane, preferentially localizing it to microvilli on leukocytes, while the cytoplasmic tail comprises 17 rich in serine and residues that serve as sites for phosphorylation and mediate interactions with cytoskeletal elements such as ERM proteins and . Post-translational modifications significantly influence L-selectin's adhesive function and stability. The protein undergoes extensive N-linked and , with site-specific patterns varying by leukocyte type—resulting in apparent molecular weights of approximately 65 kDa on lymphocytes and 100 kDa on neutrophils—which contributes to its conformational integrity and ligand interaction potential. Sialylation, particularly the addition of to form (sLe^x) motifs on N-glycans, is essential for enhancing the affinity of L-selectin for endothelial ligands, as desialylation abolishes binding activity. Sulfation, including sulfation in the CTLD and sulfation of GlcNAc residues within sLe^x glycans, further modulates binding specificity and , with 6-sulfo sLe^x structures being particularly critical for high-affinity interactions. Phosphorylation of the cytoplasmic tail, notably at serine 364 (S364) and serine 367 (S367), regulates L-selectin's intracellular associations and retention; for instance, PKC-mediated at S364 disrupts binding, thereby promoting ectodomain release. Additionally, L-selectin is subject to regulated proteolytic shedding by the metalloprotease ADAM17 (also known as TACE), which cleaves the ectodomain at a site between 321 and serine 322 (or equivalently Lys357/Ser358 in some numbering), generating a soluble form (sL-selectin) that circulates in plasma and may modulate inflammatory responses. This shedding process is calcium-dependent and triggered by cellular activation signals, ensuring rapid downregulation of surface expression during leukocyte emigration.

Expression Patterns

Cellular Distribution

L-selectin, also known as CD62L, is predominantly expressed on the surface of various leukocytes, playing a key role in their trafficking and immune surveillance. It is highly expressed on naive T and B lymphocytes, where it facilitates their recirculation through lymphoid tissues. Most monocytes and neutrophils also display significant levels of L-selectin, enabling these cells to interact with vascular during . Additionally, subsets of natural killer () cells express L-selectin, particularly those with a more mature involved in immune regulation. Transient expression of L-selectin has been observed on hematopoietic stem cells (HSCs) under specific conditions, such as during their mobilization or homing to niches, where it aids in their interactions. These patterns underscore L-selectin's role in dynamic cellular localization within the hematopoietic system. In contrast, mature erythrocytes and platelets exhibit absence or very low levels of L-selectin, consistent with their limited involvement in immune processes. Non-hematopoietic tissues generally do not express L-selectin, restricting its distribution primarily to cells of the immune . Regarding quantitative aspects, L-selectin is expressed at high levels on central T cells, supporting their long-term surveillance functions, while expression is more variable on effector T subsets, often downregulated upon .

Regulation of Expression

The expression of L-selectin, encoded by the SELL , is tightly regulated at the transcriptional level by various cytokines and transcription factors to modulate leukocyte homing and trafficking. For instance, low doses of interleukin-2 (IL-2) promote the re-expression of L-selectin on activated T cells, facilitating the formation of central memory T cells that retain high surface levels for recirculation. Similarly, interleukin-6 (IL-6) enhances L-selectin function through gp130 signaling pathways, increasing adhesive interactions in response to inflammatory cues. Transcription factors such as play a key role in upregulating SELL expression during inflammatory conditions, binding to promoter regions to drive activation. Other factors, including KLF2 and FOXO1, maintain constitutive expression in naive leukocytes, while PI3Kδ signaling downstream of cytokines like IL-2 can inhibit KLF2, leading to reduced transcription upon T cell activation. Post-translational downregulation primarily occurs through ectodomain shedding, a rapid mechanism that cleaves the extracellular domain to reduce surface L-selectin and terminate adhesion. Phorbol esters, such as phorbol 12-myristate 13-acetate (PMA), activate (PKC) pathways, triggering shedding within minutes on neutrophils and lymphocytes. Chemokine signaling, including from (IL-8) and (SDF-1), similarly induces shedding by mobilizing leukocytes and promoting activity, thereby shifting cells from rolling to firm adhesion. This process is modulated by at serine 364, which dissociates from the cytoplasmic tail, exposing the cleavage site. Internalization and dynamics further control L-selectin surface levels in response to signals. Upon stimulation with or , L-selectin is internalized via clathrin-mediated involving the μ1A subunit of the AP-1 adaptor complex, directing it to endosomes for potential or . In naive T cells, internalized L-selectin can be recycled back to the membrane, helping sustain high expression for homing; however, sustained favors , preventing reaccumulation. These dynamics ensure transient surface modulation during leukocyte without permanent loss of the protein pool. Developmentally, L-selectin expression is high on naive lymphocytes and central T cells (approximately 50,000–70,000 molecules per ), enabling efficient entry into secondary lymphoid organs. Upon antigen-driven activation or maturation into effector cells, surface levels rapidly decline through shedding and transcriptional repression, adapting cells for peripheral tissue migration rather than lymphoid recirculation. This shift is reversible in some subsets, as re-expression occurs post-activation in cells to restore homing capacity.

Ligands and Binding

Primary Ligands

L-selectin's primary ligands are predominantly sialomucins expressed on high endothelial venules (HEVs) of secondary lymphoid organs and mucosal tissues, as well as on leukocytes, featuring sulfated (sLeX) carbohydrate motifs that enable recognition by the selectin's domain. These ligands facilitate initial leukocyte-endothelial interactions through specific patterns, including sulfation and fucosylation. GlyCAM-1 (glycosylation-dependent molecule-1) is a secreted mucin-like prominently expressed on the luminal surface of HEVs in peripheral lymph nodes, serving as a key ligand for naïve homing. It bears O-linked sulfated sLeX structures essential for L-selectin binding. , a transmembrane sialomucin, is widely expressed on HEVs across lymphoid tissues and acts as a major L-selectin ligand, particularly in human tonsils, where its glycosylated forms support recirculation. Its activity depends on peripheral O-linked sLeX moieties. MAdCAM-1 (mucosal vascular addressin molecule-1), an member with a -like domain, is expressed on HEVs in mucosal lymphoid tissues such as Peyer's patches and contributes to L-selectin-dependent trafficking. It presents O-linked sLeX carbohydrates on its domain for function. PSGL-1 (, also known as CD162) is a -type expressed on most leukocytes, functioning as an L-selectin in homotypic leukocyte-leukocyte interactions during . Its N-terminal region, modified with sulfated tyrosines and core-2 O-glycans bearing sLeX, is critical for binding. Sulfated sLeX motifs represent the minimal recognition units for L-selectin across multiple scaffolds, with 6-sulfo-sLeX on core-2 branches enhancing affinity through interactions with the lectin's . These structures are prevalent on HEV ligands and require specific sulfotransferases for . Tissue-specific ligands include podocalyxin, a sialomucin expressed on HEVs and , where it supports hematopoietic via L-selectin engagement with its sulfated sLeX-bearing O-glycans. CLA (cutaneous antigen), a glycosylated primarily on PSGL-1 variants but also on vascular endothelia, functions as a carbohydrate component of L-selectin ligands, defined by HECA-452 reactivity and sulfated sLeX modifications that direct skin-homing interactions.

Binding Mechanisms

L-selectin mediates calcium-dependent binding through its N-terminal domain, which recognizes sulfated and sialylated carbohydrate structures on endothelial ligands. This interaction requires the presence of calcium ions, as with agents like EDTA abolishes binding affinity. The domain coordinates Ca²⁺ ions via conserved amino acid residues, enabling specific recognition of hydroxyl groups, particularly those modified by sulfate and . In the tethering and rolling model, L-selectin facilitates leukocyte capture from free flow by forming transient with rapid association and kinetics, characterized by an off-rate of approximately 1–10 s⁻¹ under physiological . This fast rate, which is 7–10-fold higher than that of E- or P-selectins, allows leukocytes to roll along the without firm arrest, with lifetime decreasing exponentially with applied according to the Bell model. Shear flow paradoxically enhances tether formation and rolling stability by promoting catch-slip behavior, where initial strengthens bonds before rapid at higher stresses. Multivalency plays a critical role in enhancing the of L-selectin interactions with densely glycosylated surfaces, where multiple domains bind clustered sulfated glycans simultaneously, overcoming the low of individual bonds (K_d ~ μM range). This increases overall strength, enabling effective leukocyte rolling even at low densities on endothelial cells. L-selectin binding exhibits sensitivity to environmental factors, including and , with optimal activity at physiological conditions (pH 7.4 and 37°C); deviations, such as acidification during , can reduce affinity by altering conformation or Ca²⁺ coordination. Fucosylation is essential for ligand specificity, as α1,3-linked residues in structures like (sLe^x) form the core recognition motif, with defucosylated glycans showing negligible binding. For instance, L-selectin binds avidly to fucosylated, sulfated sLe^x on glycoproteins such as GlyCAM-1.

Physiological Roles

Leukocyte Adhesion and Rolling

L-selectin plays a pivotal role in the initial capture and rolling of leukocytes on the activated during the early stages of and immune surveillance. Expressed on the microvilli of most leukocytes, L-selectin facilitates tethering from the free-flowing bloodstream to the vessel wall under hydrodynamic , typically ranging from 0.3 to 1.0 dyn/cm² in postcapillary venules. This interaction occurs through the C-type lectin domain of L-selectin binding to sialylated, sulfated glycoprotein ligands on endothelial cells, such as and GlyCAM-1, enabling rapid, reversible that slows leukocytes from bulk flow velocities of approximately 1000 μm/s to rolling speeds of 10–50 μm/s. The rolling mediated by L-selectin exhibits catch-slip bond kinetics, where increasing initially strengthens bonds (catch phase) before dissociation at higher stresses (slip phase), optimizing under physiological flow conditions. This mechanism ensures efficient leukocyte margination, positioning cells near the for subsequent activation steps. studies demonstrate that L-selectin supports leukocyte rolling independent of other selectins in untreated venules, with microvillar distribution enhancing efficiency by up to 4-fold in larger vessels. L-selectin synergizes with P-selectin and in the multi-step adhesion cascade, where initial P-selectin-mediated capture transitions to cooperative rolling involving all three selectins, amplifying leukocyte recruitment efficiency. For instance, L-selectin can mediate secondary to adherent leukocytes via interactions with PSGL-1, bridging to downstream endothelial sites. This is evident in inflammatory models, where combined selectin blockade abolishes rolling more effectively than single targeting. By facilitating rapid neutrophil margination and rolling, L-selectin contributes critically to the innate immune response, enabling swift recruitment to sites of infection or injury. In L-selectin-deficient mice, neutrophil emigration is reduced by up to 50% in thioglycollate-induced peritonitis, underscoring its role in positioning innate effectors for transmigration. This process supports host defense without relying on adaptive immunity-specific mechanisms.

Lymphocyte Homing and Trafficking

L-selectin plays a pivotal role in the homing of naive to secondary lymphoid organs, such as lymph nodes and Peyer's patches, by mediating their initial tethering and rolling on high endothelial venules (HEVs). These specialized post-capillary venules express sulfated glycoprotein ligands, including glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1) and , which are recognized by L-selectin on the surface of circulating naive T and B cells. This interaction enables the selective recruitment of lymphocytes from the bloodstream into lymphoid tissues, facilitating surveillance without broad inflammatory involvement. The recirculation pathway of lymphocytes, orchestrated in part by L-selectin, ensures continuous immune by allowing naive cells to exit the blood, traverse lymphoid organs, enter the , and return to circulation via the . In this process, L-selectin-dependent to HEV ligands supports the entry of lymphocytes into peripheral lymph nodes, where they scan for antigens presented by dendritic cells. This cyclic trafficking is essential for maintaining a diverse pool of naive lymphocytes poised for rapid , with L-selectin expression on central T cells further sustaining in non-inflamed tissues. Upon encounter with cognate in secondary lymphoid organs, L-selectin is rapidly downregulated on activated lymphocytes through proteolytic shedding, primarily mediated by ADAM17 metalloprotease, which shifts their trafficking from lymphoid recirculation to peripheral inflammatory sites. This downregulation prevents re-entry into nodes and promotes the of effector T and B cells, which upregulate alternative adhesion molecules like LFA-1 and for tissue-specific migration. The process ensures that activated lymphocytes efficiently target infection or sites while avoiding unnecessary lymphoid retention. In (GALT), L-selectin contributes to mucosal homing by binding to sulfated determinants on mucosal addressin molecule-1 (MAdCAM-1) expressed on HEVs in Peyer's patches. This interaction complements alpha4beta7 binding to MAdCAM-1, enabling the recruitment of naive and memory B cells to initiate mucosal immune responses against enteric pathogens. The sulfation of MAdCAM-1, facilitated by enzymes like GlcNAc6ST-1, enhances its avidity for L-selectin, supporting localized surveillance in the intestinal mucosa.

Neutrophil and Monocyte Recruitment

L-selectin plays a critical role in the recruitment of and to sites of through homotypic interactions mediated by (PSGL-1). On , L-selectin expressed on one cell binds to PSGL-1 on adjacent , facilitating secondary capture and clustering that promotes swarming behavior and enhances collective migration to inflammatory foci. Similarly, in , L-selectin-PSGL-1 homotypic binding supports clustering and under shear flow, contributing to efficient accumulation during the innate . During acute , L-selectin serves as a secondary in post-capillary venules, where it enables the capture of free-flowing neutrophils and monocytes by already adherent leukocytes expressing PSGL-1 ligands. This mechanism stabilizes rolling and promotes subsequent firm adhesion, particularly in larger venules where primary endothelial interactions may be insufficient. In this context, L-selectin contributes to the initial rolling step by supporting leukocyte-leukocyte contacts that bridge to the . In bacterial infections, such as those caused by , L-selectin-mediated recruitment is enhanced by the upregulation of endothelial ligands like peripheral node addressin (PNAd), which increases neutrophil trafficking to infected tissues. This ligand induction, triggered by bacterial components via signaling, amplifies L-selectin-dependent adhesion and emigration, bolstering innate defenses against pathogens. Defects in L-selectin, as observed in mice, lead to impaired and recruitment into inflammatory sites, reducing emigration by 56-78% and resulting in diminished formation during acute responses. These deficiencies also cause delayed , with slower re-epithelialization and reduced leukocyte infiltration at injury sites.

Role in Embryogenesis

L-selectin is expressed on early embryonic hematopoietic cells, including CD34-positive cells derived from fetal liver, where it facilitates interactions essential for their and homing. These progenitors, which emerge during the initial waves of hematopoiesis in the and subsequently colonize the fetal liver, utilize L-selectin to mediate rolling on endothelial surfaces under shear flow conditions. This expression pattern supports the seeding of hematopoietic stem and cells (HSPCs) into the developing niche, enabling the transition of hematopoiesis from fetal liver to in late . In the context of embryo implantation, L-selectin plays a critical role in the initial of trophoblast cells to the endometrial epithelium. Expressed on the surface of human , L-selectin binds to carbohydrate-based ligands, such as those recognized by MECA-79 and HECA-452 antibodies, which are upregulated on the luminal endometrial epithelium during the receptive window of the . This interaction promotes a transient rolling-like , allowing the to navigate the MUC1 and establish closer contact, potentially triggering downstream signals like trophinin expression for firmer attachment at pinopodes. Such mechanisms highlight L-selectin's contribution to successful maternal-fetal interface formation in early development. Studies using L-selectin mice (Sell^{-/-}) demonstrate that while the protein is important for certain processes, its absence does not lead to embryonic lethality or severe disruptions in overall development. These mice are viable and fertile at birth. This contrasts with knockouts of other selectins like E- and P-selectin, which exhibit more pronounced hematopoietic abnormalities.

Signaling and Interactions

Intracellular Signaling Pathways

Upon ligand engagement, L-selectin's short cytoplasmic tail undergoes serine , primarily at residue Ser364, mediated by (PKC) isozymes such as PKCα, PKCι, and PKCθ. This event disrupts interactions with inhibitory proteins like , facilitating downstream and promoting ectodomain shedding to regulate receptor availability. Concurrently, (MAPK)/extracellular signal-regulated kinase (ERK) pathways are activated, with rapid of p38 MAPK occurring within 1 minute and ERK1/2 peaking at 10 minutes following L-selectin cross-linking in neutrophils, contributing to enhanced and cellular responses. L-selectin signaling also recruits Src family kinases, including Fgr, Hck, and Lyn, which phosphorylate the cytoplasmic tail and associated adapters upon clustering with ligands like PSGL-1. These kinases initiate cytoskeletal rearrangements by phosphorylating ezrin at Tyr353, recruiting phosphatidylinositol 3-kinase (PI3K) and linking L-selectin to the via ERM (ezrin-radixin-moesin) proteins, thereby supporting microvilli formation and pseudopod protrusion during leukocyte and transmigration. Further downstream, L-selectin engagement activates the transcription factor in leukocytes, particularly through cross-linking with sulphatides on neutrophils, leading to nuclear translocation of the p65 subunit and induction of pro-inflammatory gene expression, such as TNF-α and IL-8. This pathway amplifies inflammatory responses by promoting production essential for leukocyte activation. To terminate signaling, feedback loops involve proteolytic shedding of the L-selectin ectodomain by ADAM17 (also known as TACE), triggered by cytoplasmic tail and PKC activity; this process, with ADAM17 cleaving at a specific enzyme-substrate site near the , rapidly downregulates surface expression and limits prolonged and signaling.

Crosstalk with Other Adhesion Molecules

L-selectin engages in inside-out signaling that activates the LFA-1 (lymphocyte function-associated antigen 1), enabling its transition to a high-affinity state for binding (intercellular adhesion molecule 1) on endothelial cells, thereby facilitating firm leukocyte adhesion after initial L-selectin-mediated rolling. This process involves L-selectin ligation triggering intracellular pathways, such as Src family kinases and Syk, which propagate signals leading to LFA-1 conformational changes and cytoskeletal rearrangements essential for stable arrest. Heterotypic interactions between L-selectin and P-selectin contribute to the formation of platelet-leukocyte aggregates, where P-selectin on activated platelets binds PSGL-1 () on leukocytes, and L-selectin on one leukocyte can bind PSGL-1 on another, stabilizing these aggregates under shear flow. These interactions enhance leukocyte recruitment to sites of vascular injury or by promoting secondary tethering and amplifying adhesive forces within the aggregates. In selectin knockout models, compensatory mechanisms involving upregulation occur during to maintain leukocyte rolling and recruitment; for instance, L-selectin-deficient mice exhibit partially preserved neutrophil trafficking due to increased expression on endothelium, as observed in models of and thioglycollate-induced . Double knockouts of L- and s reveal more severe impairments in leukocyte adhesion compared to single knockouts, highlighting the redundant yet interconnected roles of these molecules. L-selectin plays a key role in chemokine-triggered leukocyte by cooperating with signaling to induce conformational changes in β2- like LFA-1, shifting them from low- to high-affinity states for rapid firm adhesion. During rolling, L-selectin engagement shares signaling elements, such as Rap1a and PI3Kγ, with like CXCL8, ensuring synchronized activation and preventing premature while optimizing capture efficiency under flow.

Clinical and Pathological Significance

Involvement in Inflammatory Diseases

L-selectin, which normally facilitates leukocyte rolling and recruitment to sites of inflammation, contributes to pathological processes in various inflammatory diseases through dysregulated expression and shedding, leading to elevated levels of soluble L-selectin (sL-selectin) in circulation. In rheumatoid arthritis (RA), sL-selectin serves as a biomarker of disease activity, with studies showing significantly lower circulating levels compared to healthy controls, correlating inversely with synovial inflammation and joint damage. Recent studies have further elucidated its mechanistic role, demonstrating that L-selectin expression on fibroblast-like synoviocytes (RA-FLS) promotes cell migration, invasion, and pro-inflammatory cytokine production via activation of the NF-κB signaling pathway, exacerbating synovitis and cartilage destruction in RA models. Similarly, in sepsis, low sL-selectin levels at admission (<470 ng/mL) predict poor outcomes and high mortality due to impaired leukocyte function and excessive systemic inflammation. In , L-selectin drives recruitment to the vascular , initiating formation by enabling leukocyte tethering and protrusion through the endothelial barrier under conditions. This process amplifies plaque development, as evidenced by studies showing reduced infiltration and size in models treated with L-selectin inhibitors. L-selectin also contributes to by mediating leukocyte-platelet interactions at sites of vascular injury; circulating sL-selectin levels upon admission serve as a predictor of thrombotic events, reflecting heightened potential and pro-coagulant activity in inflammatory states. In inflammatory bowel disease (IBD), including , L-selectin expression is upregulated on aberrant subsets, promoting excessive homing to the gut mucosa and perpetuating chronic inflammation. This leads to disrupted epithelial integrity and immune cell accumulation in the , with genetic and functional studies confirming L-selectin's role in faulty trafficking that sustains disease flares. Animal models of provide evidence for therapeutic potential, where L-selectin blockade—via or siRNA knockdown—significantly reduces paw edema, arthritis scores, and synovial infiltration in collagen-induced models, highlighting its targetability in curbing inflammatory edema post-2020 experimental trials. Recent 2025 research further supports L-selectin's role in RA synoviocyte invasion, suggesting avenues for targeted inhibitors.

Role in Cancer Progression

L-selectin, expressed on the surface of tumor-infiltrating leukocytes such as natural killer cells and monocytes, contributes to cancer progression by facilitating their recruitment into the , where these cells can induce (VEGF) secretion to promote . This process supports tumor vascularization and growth, as recruited leukocytes interact with endothelial cells and secrete pro-angiogenic factors like VEGF in a /5-dependent manner, enhancing the formation of new blood vessels essential for nutrient supply to the tumor. Studies in various solid tumors demonstrate that this L-selectin-mediated infiltration amplifies the angiogenic switch, correlating with increased tumor burden and invasive potential. In addition to its pro-angiogenic effects, L-selectin paradoxically facilitates metastasis through enhanced adhesion between leukocytes and tumor cells, enabling circulating tumor cells to form protective clusters that evade immune detection and promote extravasation at distant sites. A comprehensive review highlights the dual role of L-selectin alongside VCAM-1 in modulating leukocyte-tumor interactions, where L-selectin binding to sialylated ligands on tumor cells strengthens heterotypic adhesions, thereby aiding metastatic dissemination while also supporting anti-tumoral immune responses under certain conditions. Experimental models, including L-selectin-deficient mice, show reduced metastatic foci formation, underscoring its contribution to tumor cell survival and colonization in organs like the lungs and liver. The soluble form of L-selectin (sL-selectin), generated by proteolytic shedding from leukocyte surfaces, serves as a potential prognostic biomarker in breast and colon cancers, with elevated plasma levels indicating advanced disease and poorer outcomes. In colorectal cancer patients, sL-selectin concentrations are elevated compared to healthy controls, particularly in those with lymph node metastasis. Similarly, in breast cancer, altered sL-selectin levels correlate with inflammatory microenvironments and tumor aggressiveness, though high L-selectin expression overall is linked to favorable survival, highlighting the need for context-specific interpretation in clinical settings. Despite these pro-tumorigenic roles, L-selectin exhibits a paradoxical anti-tumor function by enabling immune surveillance through efficient lymphocyte homing and activation against nascent tumors. L-selectin-dependent trafficking of cytotoxic T cells and natural killer cells to tumor-draining lymph nodes and the tumor site enhances anti-tumor immunity, suppressing tumor formation in preclinical models; for instance, L-selectin blockade impairs natural killer cell-mediated rejection of lymph node metastases. High L-selectin expression correlates with improved prognosis in breast and colorectal cancers by fostering an immunostimulatory microenvironment that counters metastasis. This dual nature positions L-selectin as a key modulator in the tumor microenvironment, where its effects depend on the balance between immune activation and pathological adhesion.

Implications in Reproductive Disorders

L-selectin, expressed on the surface of trophoblast cells, plays a crucial role in the initial adhesion of the blastocyst to the endometrial epithelium during human implantation. This interaction occurs through binding to carbohydrate ligands, such as sialyl Lewis x, present on the endometrial surface, facilitating the rolling and attachment necessary for successful embryo implantation. Defects in this L-selectin-mediated adhesion mechanism, particularly reduced expression or absence of L-selectin ligands like MECA-79 in the endometrium during the implantation window, have been associated with recurrent implantation failure (RIF), which can contribute to recurrent miscarriage by preventing proper blastocyst attachment. In the context of preeclampsia, a hypertensive disorder of pregnancy, L-selectin contributes to pathological leukocyte-endothelial interactions at the maternal-fetal interface. In preeclampsia, altered L-selectin dynamics, including increases in soluble serum levels, promote excessive leukocyte recruitment and activation, leading to vascular inflammation and characteristic of the condition. Reviews from 2017 onward highlight how dysregulated selectin family members, including L-selectin, exacerbate uteroplacental ischemia and systemic inflammatory responses in preeclampsia, potentially through altered shedding of soluble forms that modulate adhesion. Additionally, lower maternal serum levels of soluble L-selectin (sL-selectin) have been observed in pregnancies progressing to preeclampsia, suggesting impaired regulatory mechanisms in leukocyte trafficking. L-selectin dysregulation is also implicated in infertility associated with endometriosis, where altered expression patterns in the eutopic impair endometrial receptivity. Women with endometriosis exhibit reduced expression of L-selectin ligands in the endometrial epithelium during the mid-secretory phase, correlating with decreased attachment efficiency and higher rates of . Studies have reported lower levels of sL-selectin in serum and of endometriosis patients compared to fertile controls, potentially reflecting suppressed leukocyte and that hinders implantation. This molecular profile contributes to the 30-50% rate observed in affected women, emphasizing L-selectin's role in endometriosis-related reproductive failure. Mouse models provide insights into L-selectin's reproductive functions, though species differences limit direct translation to humans. L-selectin mice exhibit normal and implantation success, indicating that alternative pathways compensate for L-selectin deficiency in rodents. However, these models demonstrate impaired leukocyte to reproductive tissues under inflammatory conditions, underscoring L-selectin's conserved in immune modulation during despite its non-essentiality for basic implantation in mice.

Associations with Infectious Diseases

L-selectin plays a critical role in the to human immunodeficiency virus (HIV) infection by facilitating viral adhesion and entry into CD4+ T cells. The HIV-1 envelope glycoproteins bind directly to L-selectin on the surface of these cells, promoting tethering and enhancing viral infectivity, which contributes to the preferential depletion of CD4+ T lymphocytes during acute and phases of infection. Additionally, HIV-1 proteins such as Nef and Vpu induce rapid downregulation and shedding of L-selectin from infected CD4+ T cells, impairing their homing to lymphoid tissues and exacerbating immune dysfunction. This progressive loss of L-selectin expression correlates with and T-cell depletion, enabling immune evasion and disease progression. In (TB), L-selectin mediates the trafficking of naïve lymphocytes to lymph nodes and infection sites, supporting effective formation to contain . However, in HIV-TB , HIV-induced downregulation of L-selectin on + T cells disrupts this process, leading to impaired immune cell recruitment and defective integrity. A 2024 review highlights that this dysregulation in coinfected patients results in poor formation, increased bacterial dissemination, and heightened risk of extrapulmonary TB, as L-selectin-mediated homing is essential for mounting a coordinated T-cell response. Consequently, exacerbates , with reduced L-selectin function linking to chronic inflammation and worse clinical outcomes. During sepsis, excessive shedding of L-selectin from leukocytes, driven by ADAM17 activation, generates elevated soluble L-selectin (sL-selectin) levels in , which correlates with severity and . This hyper-shedding impairs recruitment to sites, potentially worsening bacterial clearance and contributing to multiple , as failure to balance shedding leads to unchecked . Furthermore, certain exploit mimicry of L-selectin ligands, such as (sLeX)-like structures, to interact with host and leukocytes, promoting and modulating immune responses during septic episodes. Emerging data from 2020–2025 indicate a potential role for L-selectin in the of severe , where elevated sL-selectin levels at admission positively correlate with pro-inflammatory markers like IL-6, reflecting endothelial activation and hyperinflammation. In hospitalized patients, higher sL-selectin concentrations are associated with increased risk of and complications linked to the , underscoring its involvement in vascular dysfunction and multi-organ injury during acute infection.

Therapeutic Targeting and Inhibitors

Monoclonal antibodies targeting L-selectin have been explored for modulating acute inflammatory responses by blocking leukocyte . Aselizumab, a humanized anti-L-selectin , was investigated in a phase II clinical trial for severely traumatized patients, where doses of 0.5, 1, or 2 mg/kg administered within 6 hours of injury showed no significant improvements in multiple organ failure, duration, ICU stay, or hospitalization compared to , despite achieving 89% saturation of L-selectin. The trial also noted dose-dependent increases in infections and , though not statistically significant versus . In a separate phase II trial for during the 2000s, aselizumab demonstrated limited efficacy, contributing to its discontinuation for this indication. Small molecule inhibitors directed at the lectin domain of L-selectin aim to disrupt its carbohydrate-binding activity and prevent leukocyte tethering. These compounds, often designed as nonoligosaccharide antagonists, have shown promise in preclinical models by inhibiting selectin-mediated cell adhesion in inflammatory contexts. For instance, dimeric and trimeric synthetic inhibitors mimicking selectin ligand components effectively block sialyl Lewis X-dependent binding, reducing leukocyte rolling on endothelium. Such inhibitors have been proposed for treating inflammatory skin diseases through interference with L-selectin functions. Multivalent glycomimetics represent an advanced class of L-selectin inhibitors, leveraging clustered mimics to enhance and therapeutic potency in and cancer. A 2021 review highlights their role in modulating selectin-mediated pathologies, including neutrophil recruitment in and tumor . For example, sialic acid-coated silver nanoparticles targeting L-selectin on s improved bacterial-mediated antitumor efficacy by depleting immunosuppressive cells, though concerns about bacterial pathogenicity persist. Similarly, sialic acid-modified liposomes reduced neutrophil accumulation, enhancing tumor targeting in cancer models. Soluble L-selectin (sL-selectin) levels serve as a for monitoring therapeutic responses in () and cancer. In , serum sL-selectin concentrations are significantly lower than in healthy controls and correlate with disease activity, providing a marker for assessing treatment efficacy. Recent 2025 analyses confirm its utility in models, where L-selectin modulation influences inflammatory responses and joint pathology. In cancer, elevated soluble selectin levels, including sL-selectin, are prognostic indicators, with reductions post-therapy linked to improved outcomes in tumor control.

References

  1. [1]
    L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and ...
    L-selectin (CD62L) is a type-I transmembrane glycoprotein and cell adhesion molecule that is expressed on most circulating leukocytes.
  2. [2]
  3. [3]
    L-selectin and its biological ligands
    This protein, belonging to the selectin family of cell-cell adhesion receptors, mediates adhesion by virtue of a C-type lectin domain at its amino terminus.
  4. [4]
    6402 - Gene ResultSELL selectin L [ (human)] - NCBI
    Aug 19, 2025 · L-selectin is expressed in memory CD4+ T cells that are smaller, proliferate well in response to tetanus toxoid, have longer telomeres, and ...Missing: chromosome | Show results with:chromosome
  5. [5]
    SELL - L-selectin - Homo sapiens (Human) | UniProtKB | UniProt
    L-selectin (SELL) is a calcium-dependent lectin that mediates cell adhesion by binding to glycoproteins on neighboring cells.
  6. [6]
    An evolutionary history of the selectin gene cluster in humans - Nature
    May 2, 2012 · In humans, three selectin genes (SELP, SELL and SELE) are located in a ∼150 kb region on chromosome 1. In order to analyze population genetic ...
  7. [7]
    Entry - *153240 - SELECTIN L; SELL - OMIM - (OMIM.ORG)
    ▻ Cloning and Expression. This glycoprotein was first identified in the mouse as the Mel-14 antigen, a lymph node homing receptor (Lnhr) also found on ...
  8. [8]
    Mouse Lymph Node Homing Receptor cDNA Clone Encodes a ...
    Analysis of messenger RNA transcripts reveals a predominantly lymphoid distribution in direct relation to the cell surface expression of the MEL-14 determinant, ...
  9. [9]
    Endoglycan, a Member of the CD34 Family, Functions as an L ...
    Jul 25, 2003 · Here, we demonstrate that endoglycan with appropriate post-translational modifications interacts with L-selectin through recognition of sLex ...
  10. [10]
    ADAM-17-independent Shedding of L-selectin - PubMed - NIH
    It has been determined that L-selectin shedding is defective in tumor necrosis factor alpha-converting enzyme (ADAM-17)-deficient cells.
  11. [11]
    ADAM17 deficiency by mature neutrophils has differential effects on ...
    These findings indicate that induced L-selectin shedding is mediated by ADAM17, and that this proteolytic process is not functionally redundant. ADAM17 ...
  12. [12]
  13. [13]
    Identification of new Rel/NF-kappaB regulatory networks by focused ...
    NF-κB is an inducible transcription factor that controls kinetically complex patterns of gene expression ... SELL (L-selectin). These novel findings provide ...
  14. [14]
  15. [15]
  16. [16]
  17. [17]
  18. [18]
  19. [19]
  20. [20]
  21. [21]
  22. [22]
  23. [23]
    C-type Lectins - Essentials of Glycobiology - NCBI - NIH
    C-type lectins are CA++-dependent glycan-binding proteins that share primary and secondary structural homology in their carbohydrate-recognition domains ...
  24. [24]
    Glycan Bound to the Selectin Low Affinity State Engages Glu-88 to ...
    The lectin domain forms Ca2+-dependent interactions with fucose and additional interactions with sialic acid and galactose. L-selectin prefers sLex modified ...
  25. [25]
    The Kinetics of L-selectin Tethers and the Mechanics of ... - NIH
    We find that the intrinsic kinetics for tether bond dissociation are 7–10-fold more rapid for L-selectin than for E- and P-selectins, and are proportional to ...
  26. [26]
    L-selectin-mediated leukocyte tethering in shear flow is controlled by ...
    The dissociation rate of single molecular bonds is expected to depend exponentially on an externally applied steady force (Bell equation) (10). Quantitative ...
  27. [27]
    The kinetics of L-selectin tethers and the mechanics of ... - PubMed
    Sep 8, 1997 · Shear uniquely enhances the rate of L-selectin transient tether formation, and conversion of tethers to rolling adhesions, providing further ...
  28. [28]
    Glycoforms of human endothelial CD34 that bind L-selectin carry ...
    Several candidate L-selectin ligands have been identified in the HEVs of secondary lymphoid tissues, including GlyCAM-1 (Sgp50), CD34 (Sgp90), podocalyxin-like ...
  29. [29]
    Chemical Lectinology: Tools for Probing the Ligands and Dynamics ...
    Multivalency, the presence of numerous glycan ligands on a single scaffold, can dramatically increase the avidity of lectins for their oligomeric targets. As a ...
  30. [30]
    Glycopeptide Analogues of PSGL-1 Inhibit P-Selectin In Vitro and In ...
    Blockade of P-selectin/PSGL-1 interactions holds significant potential for treatment of disorders of innate immunity, thrombosis, and cancer.
  31. [31]
    L Selectin - an overview | ScienceDirect Topics
    GlyCAM-1 undergoes modification with core 2 O-glycans that are sialylated, fucosylated, and sulfated when it binds to the L-selectin. Endothelial cells express ...<|control11|><|separator|>
  32. [32]
  33. [33]
    L-selectin–mediated Leukocyte Adhesion In Vivo - PubMed Central
    Rolling leukocytes may adhere firmly by activation- induced interactions of leukocyte integrins with endothelial counterreceptors and transmigrate through the ...<|control11|><|separator|>
  34. [34]
    Sequential contribution of L- and P-selectin to leukocyte rolling in vivo
    Leukocyte recruitment into inflammatory sites is initiated by a reversible transient adhesive contact with the endothelium called leukocyte rolling, ...
  35. [35]
  36. [36]
    Lymphocyte–HEV Interactions in Lymph Nodes of a Sulfotransferase ...
    The interaction of L-selectin expressed on lymphocytes with sulfated sialomucin ligands such as CD34 and GlyCAM-1 on high endothelial venules (HEV) of lymph ...
  37. [37]
    Binding of L-Selectin to the Vascular Sialomucin CD34 - Science
    A recombinant L-selectin stains high endothelial venules (HEVs) in lymph nodes and recognizes sulfated carbohydrates found on two endothelial glycoproteins.
  38. [38]
    L-selectin: Role in Regulating Homeostasis and Cutaneous ... - NIH
    L-selectin is a key adhesion molecule that regulates both the migration of leukocytes at sites of inflammation and the recirculation of lymphocytes between ...Missing: ESL- | Show results with:ESL-
  39. [39]
    Molecular Mechanisms of Lymphocyte Homing to Peripheral Lymph ...
    Lymphocytes migrate from the blood into tissues and secondary lymphoid organs, and return back to the blood via lymph vessels and the thoracic duct (1). The ...
  40. [40]
    L-Selectin Shedding Does Not Regulate Constitutive T Cell ...
    These results suggest that the ability to shed L-selectin is not required for T cell recirculation and homing to PLNs.Flow Cytometric Analysis · Confocal Microscopy · Results
  41. [41]
    The Shedding of CD62L (L-Selectin) Regulates the Acquisition of ...
    Upon encounter, with matched tumor lines, antigen reactive T cells rapidly lose CD62L expression and this was associated with the acquisition of CD107a. By ...
  42. [42]
    Naive, effector and memory CD8 T-cell trafficking - PubMed Central
    All three members of the selectin family of proteins play important roles in regulating CD8 T-cell trafficking [8]. L-selectin (CD62L) is expressed by all naive ...
  43. [43]
    GlcNAc6ST-1-Mediated Decoration of MAdCAM-1 Protein with L ...
    MAdCAM-1 protein was co-localized with L-selectin ligand carbohydrates at the luminal surface of HEV-like vessels in situ. GlcNAc6ST-1 preferentially utilizes ...
  44. [44]
    Role of MAdCAM-1-Expressing High Endothelial Venule-Like ... - NIH
    These findings suggest that interactions between MAdCAM-1 and α4β7 integrin and/or unsulfated sLeX and L-selectin may become a dominant mechanism for ...
  45. [45]
    Molecules controlling lymphocyte migration to the gut - PMC
    Multistep model of lymphocyte homing into the gut. The five separate steps in lymphocyte trafficking from the blood into gut are shown.
  46. [46]
  47. [47]
  48. [48]
    L-selectin-deficient mice have impaired leukocyte recruitment ... - NIH
    Abstract. L-selectin, a cell surface adhesion molecule that is expressed by most leukocytes, mediates leukocyte rolling along vascular endothelium at sites ...
  49. [49]
    Delayed Wound Healing in the Absence of Intercellular Adhesion ...
    L-selectin-deficient (L-selectin−/−) mice have decreased trauma-induced rolling of leukocytes in the exteriorized mesentery and decreased rolling in cremaster ...
  50. [50]
    Expression of an L-selectin ligand on hematopoietic progenitor cells
    L-selectin, an adhesion protein best known for regulating leukocyte attachment to endothelium, is characteristically expressed on the earliest hematopoietic ...Missing: embryonic seeding
  51. [51]
    Relationship between selectin-mediated rolling of hematopoietic ...
    Jan 15, 2000 · We studied the interaction of human HSPC from adult bone marrow (ABM) and fetal liver (FL) with E-, P-, and L-selectin surfaces in a flow ...
  52. [52]
    Trophoblast L-Selectin-Mediated Adhesion at the Maternal-Fetal Interface
    ### Key Findings on L-selectin in Trophoblast Adhesion During Implantation
  53. [53]
    An integrated view of L-selectin and trophinin function in human ...
    This review describes the potential roles of L-selectin, ErbB4/HB-EGF and trophinin in human embryo implantation, and proposes a new way of understanding these ...
  54. [54]
    Hematopoietic Progenitor Cell Rolling in Bone Marrow Microvessels
    Rolling did not involve L-selectin, but was partially reduced in wild-type mice treated with antibodies to P- or E-selectin and in mice that were deficient in ...
  55. [55]
    002917 - L-selectin KO Strain Details - The Jackson Laboratory
    Mice homozygous for the Selltm2Hyn mutation are viable and fertile. They are characterized by hypoplastic lymph nodes because of failure of lymphocytes to roll ...Missing: fetal liver
  56. [56]
  57. [57]
  58. [58]
    L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and ...
    L-selectin (CD62L) is a type-I transmembrane glycoprotein and cell adhesion molecule that is expressed on most circulating leukocytes.Missing: evolutionary | Show results with:evolutionary
  59. [59]
    Selectin-Mediated Signaling—Shedding Light on the Regulation of ...
    This article will focus on signaling cascades activated in neutrophils downstream of selectin binding to its ligands, the resulting effects on integrin activity ...
  60. [60]
    Platelet-Leukocyte Cross Talk in Whole Blood
    As visualized previously, platelets and leukocytes may form platelet-leukocyte aggregates or conjugates (PLAs), mainly via platelet-expressed P-selectin and its ...
  61. [61]
    Selectins and Their Ligands: Current Concepts and Controversies
    Before the identification of selectins as a family of related adhesion molecules which mediate leukocyte rolling, the role of L-selectin (then known as the MEL- ...
  62. [62]
    Leukocyte ligands for endothelial selectins: specialized ...
    Here we review evidence that PSGL-1, CD44, and ESL-1 on mature leukocytes are physiologic glycoprotein ligands for endothelial selectins.Psgl-1 · Cd44 · Additional Ligands For...<|control11|><|separator|>
  63. [63]
    Selectins and chemokines use shared and distinct signals to ...
    Mar 28, 2018 · Chemokine signaling activates β2 integrins to cause arrest. Despite extensive study, key aspects of these signaling cascades remain unresolved.Rap1a And Pip5kγ90... · Rap1a And Pi3kγ Cooperate... · Selectins And Chemokines...
  64. [64]
    Selectins and chemokines use shared and distinct signals to ... - NIH
    Mar 28, 2018 · Selectin signaling activates β2 integrins to slow rolling velocities. Chemokine signaling activates β2 integrins to cause arrest.Rap1a And Pip5kγ90... · Rap1a And Pi3kγ Cooperate... · Selectins And Chemokines...
  65. [65]
    Regulation of tumor angiogenesis by the crosstalk between innate ...
    Tumor-infiltrating NK cells modulate tumor angiogenesis also through the secretion of VEGF and angiogenin in a STAT-3/5-dependent manner. This pro-angiogenic ...
  66. [66]
    The crossroad between tumor and endothelial cells - PMC - NIH
    Sep 26, 2024 · There are three classes of selectins: L-selectin, expressed on leukocytes ... Tumor-infiltrating leukocytes are markedly increased following VEGF ...
  67. [67]
    Dual implication of endothelial adhesion molecules in tumor ...
    In addition to the adhesion to endothelium, L-Selectin holds an important role in leukocytes homing by allowing migration to lymph nodes [29,30]. Intercellular ...
  68. [68]
  69. [69]
    L-Selectin expression is associated with inflammatory ... - NIH
    Jan 8, 2021 · L-Selectin expression is associated with inflammatory microenvironment and favourable prognosis in breast cancer - PMC.Missing: sL- colon
  70. [70]
    Suppression of tumor formation in lymph nodes by L-selectin ...
    NK cells play a critical role in tumor immunosurveillance (15–17). They express both activating and inhibitory receptors, and the integration of signals derived ...Distinct Nk Cell Subsets In... · L-Selectin Ligands Mediate... · Nk Cells Control Tumor...
  71. [71]
  72. [72]
    Trophoblast L-selectin Adhesion at Maternal-Fetal Interface
    Trophoblast adhesion to the uterine wall is the requisite first step of implantation and, subsequently, placentation. At the maternal-fetal interface, ...
  73. [73]
    Expression of L-selectin ligand MECA-79 as a predictive ... - PubMed
    The absence of these ligands could lead to recurrent implantation failure (RIF) in some of these couples. Methods: Twenty fertile women and 20 patients with ...
  74. [74]
    Expression of L-selectin ligand MECA-79 as a predictive ... - NIH
    The absence of these ligands could lead to recurrent implantation failure (RIF) in some of these couples. ... L-selectin ligand correlates with unsuccessful ...
  75. [75]
    Maternal, Fetal, and Placental Selectins in Women With Pre-eclampsia
    We can thus speculate that the increased placental L-selectin in early-onset pre-eclampsia could lead to increased leucocyte activation and therefore atherosis ...
  76. [76]
    Role of selectins and their ligands in human implantation stage
    This review focuses on the current progress of research on the role of selectins and their ligands in the human implantation process.
  77. [77]
    Adhesion molecules changes at 20 gestation weeks in pregnancies ...
    In women with subsequent preeclampsia, sL-selectin and sVCAM-1 concentrations were significantly lower, whereas sE-selectin, sP-selectin and sICAM-1 levels were ...
  78. [78]
    L-Selectin ligands in human endometrium: comparison of fertile and ...
    Hence the pattern of expression of L-selectin ligands may be a factor that contributes to endometrium-related infertility through control of high and low ...
  79. [79]
    Lselectin Levels in Patients with Endometriosis
    Jan 18, 2018 · Abstract. Objective: To investigate the L-selectin profile in endometriotic patients. Methods: This was a cross-sectional study. Subjects were ...Missing: low soluble
  80. [80]
    The endometria of women with endometriosis exhibit dysfunctional ...
    It is composed of several soluble and surface proteins assembled to protect the host tissue from pathogens, apoptotic, neoplastic, or foreign cells. Upon ...
  81. [81]
    Subcellular localization of L-selectin ligand in the endometrium ...
    Jun 15, 2012 · It is reasonable that mutant mice deficient in the L-selectin gene show no defect in implantation even though a microarray analysis of mouse ...
  82. [82]
    Evolutionary divergence of embryo implantation in primates - Journals
    Oct 17, 2022 · Mouse SELL knockout embryos still implant, suggesting that these interactions are not essential for embryo adhesion [122]. In humans, l-selectin ...
  83. [83]
    HIV-1 targets L-selectin for adhesion and induces its shedding for ...
    Jul 19, 2018 · We identify L-selectin (CD62L) as a viral adhesion receptor on CD4 + T cells. The binding of viral envelope glycans to L-selectin facilitates HIV entry and ...
  84. [84]
    HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface ...
    This study reveals that CD62L is strongly downregulated on primary CD4+ T lymphocytes upon infection with human immunodeficiency virus type 1 (HIV-1). Reduced ...
  85. [85]
    The Role of L-Selectin in HIV Infection - Frontiers
    The progressive loss of L-selectin expression in infected CD4+ T cells correlated with the viral infection suggesting that the shedding of L-selectin is viral ...
  86. [86]
    L-selectin-dependent and -independent homing of naïve ... - NIH
    Jul 5, 2023 · Our study suggests that both L-selectin-dependent and -independent pathways contribute to naïve lymphocyte entry into mLN during M. tuberculosis infection.
  87. [87]
    [PDF] L-selectin in Tuberculosis-HIV Coinfection: Linking Immune ...
    Apr 27, 2024 · This review aims to elucidate the role of L-selectin in TB-HIV coinfection, focusing on its implications for immune activation and disease ...
  88. [88]
    (PDF) Impact of L-selectin on Immune Cell Trafficking in ...
    Apr 7, 2024 · This review provides a comprehensive overview of the impact of L-selectin on immune cell trafficking in TB and HIV coinfection, highlighting its ...
  89. [89]
    Soluble adhesion molecules as markers for sepsis and the potential ...
    Feb 18, 2014 · Clinical studies show that L-selectin is shed and detected at elevated levels in the plasma during the systemic inflammatory response [22].
  90. [90]
    [PDF] Soluble adhesion molecules as markers for sepsis and the potential ...
    Feb 18, 2014 · Five soluble adhesion molecules are associated with sepsis, specifically, E-selectin, L-selectin and P-selectin, intercellular adhesion molecule ...<|control11|><|separator|>
  91. [91]
    Evaluation of admission levels of P, E and L selectins as predictors ...
    Jan 21, 2022 · The aim of this work was to evaluate circulating soluble selectins P, E and L at the time of hospital admission as predictors for upcoming thrombosis.Missing: 2020-2025 | Show results with:2020-2025
  92. [92]
    The effect of anti-L-selectin (aselizumab) in multiple traumatized ...
    Aselizumab was associated with a higher rate of infections and leucopenia; however, this difference was not significantly different compared with placebo.Missing: psoriasis | Show results with:psoriasis
  93. [93]
    Cell adhesion antagonists: therapeutic potential in asthma ... - Gale
    2.1.1 Current Therapeutic Approaches Targeting Selectins in Lung Inflammation. At least five selectin inhibitors have reached phase I and II clinical trials ...
  94. [94]
    Thera-SAbDab - OPIG
    L-Selectin. Heavy Chain ... Phase-II. Estimated Status (Feb '25), Discontinued. Recorded Developmental Technology. INN Year Proposed, 2003. INN Year ...
  95. [95]
    Novel Synthetic Inhibitors of Selectin-Mediated Cell Adhesion ...
    These compounds were assayed for the ability to inhibit the binding of sialyl Lewisx (sLex, 2) bearing HL-60 cells to E-, P-, and L-selectin fusion proteins. We ...Abstract · Subjects · Supporting Information...
  96. [96]
    Inhibitors of selectin functions in the treatment of inflammatory skin ...
    Selectins are single-chain transmembrane adhesion molecules, which have been named for their lectin-like domain that attaches to carbohydrate ligands presented ...
  97. [97]
    Targeting Selectins Mediated Biological Activities With Multivalent ...
    Dec 2, 2021 · This review briefly summarizes the selectin-mediated various diseases such as thrombosis, cancer and recent progress in the different types of multivalent ...Missing: glycomimetics | Show results with:glycomimetics
  98. [98]
  99. [99]
  100. [100]
    Serum-soluble selectin levels in patients with rheumatoid arthritis ...
    The sL-selectin level was significantly lower in RA patients compared to healthy subjects. Serum sP-selectin levels were not significantly different among the ...Missing: cancer therapy
  101. [101]
    Serum‐Soluble Selectin Levels in Patients with Rheumatoid Arthritis ...
    Mar 18, 2004 · Serum levels of selectins may provide a useful additional marker for disease activity in RA patients and for disease severity in SSc patients.Missing: biomarker cancer
  102. [102]
    L-selectin Promotes Migration, Invasion and Inflammatory Response ...
    Jan 16, 2025 · In summary, we show that L-selectin enhances the migration and invasion of RA-FLSs through the activation of NF-κB signaling pathways, ...Missing: production | Show results with:production
  103. [103]
    Selectins in Biology and Human Disease: Opportunity in E ... - NIH
    Jun 9, 2024 · Notably, soluble selectin levels are adversely prognostic in multiple disease states [52-55]. Soluble L-selectin is formed from L-selectin ...